Doctors at AIIMS, Delhi are in the process of developing a low cost antibody-based adaptive cellular therapy for treatment of ...

Novel vaccine platform improved protection against diverse influenza subtypes when tested in animal models and human ...

Doctors at AIIMS, Delhi are developing a low-cost, antibody-based adaptive cellular therapy targeting multiple myeloma, a ...

It is possible to substantially enhance these antibodies’ therapeutic potential via humanization, effectively reducing ...

Doctors at AIIMS, Delhi are in the process of developing a low cost antibody-based adaptive cellular therapy for treatment of multiple myeloma, a form of blood cancer. This kind of therapy is expected ...

Stanford Medicine scientists have designed a way to make our seasonal influenza vaccinations more broadly effective and ...

Northwestern Medicine scientists have developed a method for identifying reactive cysteines on peptide antigens within the ...

The TRACeR I platform was incorporated into a humanized antibody fragment in a bispecific T-cell engager (BiTE) format. When ...

Boster Biological Technology is revolutionizing molecular biology with its advanced recombinant protein expression and custom ...

Microfluidic technology enables high-throughput, droplet-based antibody discovery in fully human antibody mice.

Host genetics play a significant role in shaping immune responses to different strains in the influenza vaccine, ...